Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study

Adding pertuzumab to trastuzumab (both monoclonal antibodies targeting human epidermal growth factor receptor 2 [HER2]) has proven survival benefits when combined with chemotherapy for patients with HER2‐positive breast cancer. The combination of pertuzumab and trastuzumab together in 1 vial for sub...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Clin Pharmacol
मुख्य लेखकों: Kirschbrown, Whitney P., Wynne, Chris, Kågedal, Matts, Wada, Russ, Li, Hanbin, Wang, Bei, Nijem, Ihsan, Badovinac Crnjevic, Tanja, Gasser, Helena, Heeson, Sarah, Eng‐Wong, Jennifer, Garg, Amit
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: John Wiley and Sons Inc. 2018
विषय:
Pharmacokinetics
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7027517/
https://ncbi.nlm.nih.gov/pubmed/30570763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1362
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन